Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Dose Escalation Clinical Trial of Apatinib Tablets Plus Docetaxel as Second-line Treatment in Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

NCT03071042 is registered in ClinicalTrials.gov with Sir Run Run Shaw Hospital as lead sponsor.

NCT NCT03071042
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03071042 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Dose Escalation Clinical Trial of Apatinib Tablets Plus Docetaxel as Second-line Treatment in Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Lead sponsor
Sir Run Run Shaw Hospital
Phase
Phase 1
Overall status
Unknown status
Start date
October 31, 2015
Completion date
June 30, 2018
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic gastric adenocarcinoma